Abstract: A method for treating liver cancer, particularly in subjects exhibiting homologous recombination deficiency (HRD) positivity, includes using hydroxyureamethyl acylfulvene. The compound can be administered as a monotherapy or in combination with other chemotherapeutic agents and/or radiotherapy.

Abstract: A method of treating cancer includes administering a combination of active agents comprising a therapeutically effective amount of an acylfulvene, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an anti-CD20 antibody. The anti-CD20 antibody can be selected from rituximab, obinutuzumab, ofatumumab, and tositumomab. The cancer may be a B-cell cancer.

Abstract: A machine learning system and method for predicting blood-brain barrier permeability is provided. The system obtains samples of data associated with molecules from various data sources, converts the samples into structural representations, and generates a plurality of features from the structural representations, such as fingerprint representations. Tests are executed on the features to determine blood-brain barrier permeability dependency, The system analyzes the ratio of permeable to non-permeable samples in the samples of data and augments the samples with synthetic data to create a balanced dataset if an imbalance between the types of samples is detected. The system reduces the features utilized for training the machine learning utilizing a technique, such as logistic regression, to create a selected set of features for the balanced dataset.

Abstract: This method involves treating individuals diagnosed with renal cell carcinoma using a therapeutically effective amount of hydroxyureamethyl acylfulvene. The treatment is applicable to various types of renal cell carcinoma, including clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma, and medullary carcinoma.

Abstract: A method of treating breast cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a PARP inhibitor. Compositions and kits of the same are included herein. The breast cancer may be refractory to various PARP inhibitors.

Abstract: A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of Bortezomib, Ibrutinib or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein.

Abstract: Disclosed are systems and methods that provide a novel framework for decision intelligence (DI)-based drug determinations. The disclosed framework can leverage a dynamically and recursively trained artificial intelligence/machine learning (AI/ML) ensemble configuration to analyze genomic data and functions that arrive from the same. Ensemble determinations and applications can increase the accuracy of the training, validation, and external testing sets associated with drug discovery and personalization. The ensemble-based computerized framework can be configured for analysis of samples using an ensemble algorithm trained with a binary mutation data and a hierarchical clustering data, which can enable determinations of drug efficacy and patent stratification.

Abstract: A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a spironolactone or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein.

Abstract: The methods include treating cancer by the administration of an effective amount of acylfulvene to a subject in need thereof and an effective amount of radiation. The irradiation occurs before or concurrently with the administration of the effective amount of acylfulvene.

Abstract: A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a PARP inhibitor or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein.

Abstract: A method for treating a subject in need thereof having a bone or blood cancer, or a cancer that metastasizes to bone that includes administering to the subject an effective amount of hydroxyureamethyl acylfulvene.

Abstract: This invention provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value.

Abstract: This invention provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value.

Abstract: The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer.

Abstract: The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer.